Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

NCT06033833 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06033833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06033833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
September 5, 2023
Completion date
September 22, 2026
Enrollment
335 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

asthma